TP53 and cancer: However, in some studies, the surface modification of the LNCs with active ligands (antibody, peptide, etc.)was studied, either because they did not contain ferrocifens [26] or because the recognition of certain cancer cells by active targeted LNCs was expected to allow an even more specific accumulation in the tumor cells, as observed, for example, with NFL P53 LNCs [95].